InvestSMART

MGC Pharmaceuticals Ltd (ASX: MXC) - Announcements

Current share price for MXC : $0.420 0.01 (2.44%)+

ASX company news and announcements for MGC Pharmaceuticals Ltd (MXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All MGC Pharmaceuticals Ltd (MXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than MGC Pharmaceuticals Ltd (MXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for MGC Pharmaceuticals Ltd (MXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Company Presentation - October 2019 1 Oct 2019 9:42AM $0.039 $0.420 risen by 976.92%
$18 200 Prescription Milestone Passed in Australia & UK 18 Sep 2019 9:37AM $0.040 $0.420 risen by 950%
$18 Issue of $1m PO Shares and Issue of Options - Appx 3B 16 Sep 2019 6:36PM $0.040 $0.420 risen by 950%
$18 $1m Priority Offer Closed Oversubscribed 11 Sep 2019 1:10PM $0.040 $0.420 risen by 950%
$18 Priority Offer Closed - Additional Issues Completed Appx 3B 10 Sep 2019 8:57AM $0.041 $0.420 risen by 924.39%
$18 Epilepsy Clinical Study Comparing CannEpil to 100% CBD 3 Sep 2019 9:10AM $0.039 $0.420 risen by 976.92%
$18 Placement Settlement Complete, Info on the Priority Offer 29 Aug 2019 1:38PM $0.040 $0.420 risen by 950%
$18 Appendix 3B - Placement and Priority Offer Prospectus 29 Aug 2019 1:18PM $0.041 $0.420 risen by 924.39%
$18 Prospectus 29 Aug 2019 12:30PM $0.042 $0.420 risen by 900%
$18 Appendix 4E and Audited 2019 Financial Report 29 Aug 2019 8:05AM $0.039 $0.420 risen by 976.92%
$18 Approval Granted for Large-Scale Research Project with IHPS 27 Aug 2019 8:07AM $0.044 $0.420 risen by 854.55%
$18 Trial on the Effect of CannEpil on Driver Competency 23 Aug 2019 9:50AM $0.049 $0.420 risen by 757.14%
$18 Reinstatement to Official Quotation 21 Aug 2019 1:15PM $0.050 $0.420 risen by 740%
$18 Canaccord to Lead LSE Listing and $4.75m Placement Closed 21 Aug 2019 1:15PM $0.050 $0.420 risen by 740%
$18 Suspension from Official Quotation 21 Aug 2019 10:40AM $0.050 $0.420 risen by 740%
$18 Trading Halt 19 Aug 2019 9:42AM $0.050 $0.420 risen by 740%
$18 MXC 100 Patient Milestone in Aus, Onboards Tetra Health 13 Aug 2019 9:21AM $0.053 $0.420 risen by 692.45%
$18 MGC Signs Agreement for Construction of GMP Pharma Facility 8 Aug 2019 6:50PM $0.050 $0.420 risen by 740%
$18 YuShop Completes Chinese Market Test, Sales to Commence 7 Aug 2019 9:01AM $0.047 $0.420 risen by 793.62%
$18 Additional Information on Ground-breaking Research 29 Jul 2019 3:53PM $0.053 $0.420 risen by 692.45%
$18 MGC Research- Effectiveness of Cannabinoids on Brain Cancers 24 Jul 2019 8:24AM $0.053 $0.420 risen by 692.45%
$18 June Quarterly Activity and Cashflow Report 11 Jul 2019 8:59AM $0.052 $0.420 risen by 707.69%
$18 Exercise of 6.5c Listed Options Tranche 2 - Appendix 3B 5 Jul 2019 5:17PM $0.051 $0.420 risen by 723.53%
$18 Exercise of 6.5c Listed Options Tranche 1 - Appendix 3B 21 Jun 2019 6:29PM $0.054 $0.420 risen by 677.78%
$18 Germany, Austria & Switzerland Distribution Agreement Signed 21 Jun 2019 9:41AM $0.052 $0.420 risen by 707.69%

526 - 550 of 818 results

Page 22 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.